This multicenter randomized controlled trial aims to evaluate the efficacy of a novel diagnostic approach combining PCR and CRISPR/Cas12a technology for early targeted anti-infective therapy in patients with severe pneumonia. The study is sponsored by the Chinese Medical Association and is currently recruiting participants across multiple ICU units in Nanjing, China. If successful, this approach could significantly reduce the time to appropriate antibiotic therapy, potentially improving patient outcomes and reducing healthcare costs associated with prolonged ICU stays and complications from antibiotic resistance. The market for rapid diagnostic tools in infectious diseases is growing, driven by the increasing prevalence of antibiotic-resistant infections and the need for timely interventions. This trial positions the sponsor favorably within this expanding market, particularly in the context of severe pneumonia management.